Format

Send to

Choose Destination
Hum Vaccin Immunother. 2013 Apr;9(4):784-9. doi: 10.4161/hv.23085. Epub 2013 Jan 17.

Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors.

Author information

1
Department of Molecular Medicine; Morsani College of Medicine; University of South Florida; Tampa, FL USA.

Abstract

Numerous molecular effects have been attributed to histone deacetylase inhibitors (HDACI's), including the induction of major histocompatibility (MHC) genes. Here we report that one FDA approved HDACI, Vorinostat, and a second HDACI currently in clinical trials, Entinostat, reduce the ratio of class II associated invariant peptide (CLIP) to the MHC class II molecule, HLA-DR, indicating an increase in the non-CLIP peptides bound to HLA-DR. The HDACI effects are apparent with immortalized B-cells, HLA-DR constitutive melanoma cells and with melanoma cells expressing HLA-DR due to transformation with an expression vector for the HLA-DR gene co-activator, CIITA. Entinostat treatment leads to upregulation of Cathepsin L1, and the HLA-DR peptidome of the Entinostat treated cells is consistent with increased Cathepsin L1 mediated proteolysis. These results indicate that HDACI treatments may alter the HLA-DR peptidome of cells in patients and provide a way to identify novel immunogens for vaccinations and the study of autoantigens.

KEYWORDS:

HLA-DR peptide occupancy; antigenic peptide; cathepsin; histone deacetylase inhibitors; major histocompatibility class II

PMID:
23328677
PMCID:
PMC3903896
DOI:
10.4161/hv.23085
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center